NO20016246D0 - Selective iGluR5 receptor antagonist for the treatment of migraine - Google Patents

Selective iGluR5 receptor antagonist for the treatment of migraine

Info

Publication number
NO20016246D0
NO20016246D0 NO20016246A NO20016246A NO20016246D0 NO 20016246 D0 NO20016246 D0 NO 20016246D0 NO 20016246 A NO20016246 A NO 20016246A NO 20016246 A NO20016246 A NO 20016246A NO 20016246 D0 NO20016246 D0 NO 20016246D0
Authority
NO
Norway
Prior art keywords
migraine
treatment
receptor antagonist
iglur5 receptor
selective iglur5
Prior art date
Application number
NO20016246A
Other languages
Norwegian (no)
Other versions
NO20016246L (en
Inventor
David Bleakman
Amy Suzon Chappell
Sandra Ann Filla
Kirk Willis Johnson
Paul Leslie Ornstein
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO20016246D0 publication Critical patent/NO20016246D0/en
Publication of NO20016246L publication Critical patent/NO20016246L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
NO20016246A 1999-07-06 2001-12-19 Selective iGluR5 receptor antagonist for the treatment of migraine NO20016246L (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14248599P 1999-07-06 1999-07-06
US15116599P 1999-08-27 1999-08-27
PCT/US2000/016297 WO2001001972A2 (en) 1999-07-06 2000-06-27 SELECTIVE iGluR5 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF MIGRAINE

Publications (2)

Publication Number Publication Date
NO20016246D0 true NO20016246D0 (en) 2001-12-19
NO20016246L NO20016246L (en) 2002-03-04

Family

ID=26840135

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20016246A NO20016246L (en) 1999-07-06 2001-12-19 Selective iGluR5 receptor antagonist for the treatment of migraine

Country Status (28)

Country Link
US (4) US6566370B1 (en)
EP (1) EP1200073B1 (en)
JP (1) JP4619595B2 (en)
KR (1) KR20020024300A (en)
CN (1) CN1230174C (en)
AR (1) AR029373A1 (en)
AU (1) AU773304B2 (en)
BR (1) BR0012175A (en)
CA (1) CA2378613C (en)
CZ (1) CZ20014488A3 (en)
DE (1) DE60032905T2 (en)
DK (1) DK1200073T3 (en)
DZ (1) DZ3209A1 (en)
EA (1) EA004290B1 (en)
ES (1) ES2278619T3 (en)
HK (1) HK1047036A1 (en)
HR (1) HRP20020013A2 (en)
HU (1) HUP0202253A3 (en)
IL (1) IL146697A0 (en)
MX (1) MXPA01012726A (en)
MY (1) MY133503A (en)
NO (1) NO20016246L (en)
NZ (1) NZ515616A (en)
PE (1) PE20010299A1 (en)
PT (1) PT1200073E (en)
SK (1) SK112002A3 (en)
TR (1) TR200200066T2 (en)
WO (1) WO2001001972A2 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2574801A (en) 1999-12-22 2001-07-03 Eli Lilly And Company Selective iGLUR5 receptor antagonists
EP1351951A2 (en) * 2001-01-05 2003-10-15 Eli Lilly And Company Pyrrolidinylmethyl- and piperidinyl substituted decahydroisoquinolines as excitatory amino acid receptor antagonists
SK8242003A3 (en) * 2001-01-05 2004-01-08 Lilly Co Eli Excitatory amino acid receptor antagonists
AU2002241565A1 (en) * 2001-01-05 2002-07-16 Eli Lilly And Company Excitatory amino acid receptor antagonist and 5-ht1f agonist combination: a method for the treatment of neurological disorders
WO2002053556A2 (en) * 2001-01-05 2002-07-11 Eli Lilly And Company Pyrrolidinylmethyl substituted decahydroisoquinolines as excitatory amino acid receptor antagonists
US6924294B2 (en) 2001-01-05 2005-08-02 Eli Lilly And Company Excitatory amino acid receptor antagonists
US7205313B2 (en) 2001-01-05 2007-04-17 Eli Lilly And Company Excitatory amino acid receptor antagonists
ES2306690T3 (en) * 2001-01-05 2008-11-16 Eli Lilly And Company ANTAGONISTS OF RECEIVERS OF EXCITATORY AMINO ACIDS.
GB0128996D0 (en) 2001-12-04 2002-01-23 Novartis Ag Organic compounds
US20040082606A1 (en) * 2001-12-20 2004-04-29 Khau Vien Van Excitatory amino acid receptor antagonists
JP2005529892A (en) 2002-04-26 2005-10-06 イーライ・リリー・アンド・カンパニー Decahydroisoquinoline-3-carboxylic acid ester prodrug as an analgesic
US7960436B2 (en) 2006-06-05 2011-06-14 Valeant Pharmaceuticals International Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
KR20090079191A (en) 2006-08-23 2009-07-21 밸리언트 파마슈티컬즈 인터내셔널 Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators
US8993593B2 (en) 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
US8722929B2 (en) 2006-10-10 2014-05-13 Valeant Pharmaceuticals International N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators
ATE538084T1 (en) 2006-11-28 2012-01-15 Valeant Pharmaceuticals Int BICYCLIC 1,4-RETIGABINE ANALOGAS AS POTASSIUM CHANNEL INHIBITORS
US8367684B2 (en) 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
US8563566B2 (en) 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
US7786146B2 (en) 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
JP2020529975A (en) 2017-07-31 2020-10-15 ノバルティス アーゲー Use of Maboglulanto to reduce cocaine use or prevent relapse of cocaine use
US10591492B2 (en) 2018-03-05 2020-03-17 Janssen Pharmaceutica Nv Assays to detect neurodegeneration

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5284957A (en) * 1992-09-03 1994-02-08 Eli Lilly And Company Excitatory amino acid receptor antagonists
US5356902A (en) * 1992-11-06 1994-10-18 Eli Lilly And Company Decahydroisoquinoline compounds as excitatory amino acid receptor antagonists
US5446051A (en) 1994-05-31 1995-08-29 Eli Lilly And Company Aryl-spaced decahydroisoquinoline-3-carboxylic acids as excitatory amino acid receptor antagonists
US5767117A (en) 1994-11-18 1998-06-16 The General Hospital Corporation Method for treating vascular headaches
HUP0002030A3 (en) 1997-04-07 2002-01-28 Lilly Co Eli Use of glur5 receptorantagonists for the treatment of pain
ATE240299T1 (en) 1999-07-06 2003-05-15 Lilly Co Eli THIS PRODRUGS OF DECAHYDROISCHINOLINE-3- CARBOXYLIC ACID

Also Published As

Publication number Publication date
US20040192722A1 (en) 2004-09-30
DE60032905T2 (en) 2007-10-18
ES2278619T3 (en) 2007-08-16
HRP20020013A2 (en) 2003-08-31
US6566370B1 (en) 2003-05-20
MY133503A (en) 2007-11-30
HUP0202253A3 (en) 2003-12-29
IL146697A0 (en) 2002-07-25
PE20010299A1 (en) 2001-03-07
EP1200073A2 (en) 2002-05-02
TR200200066T2 (en) 2002-04-22
JP4619595B2 (en) 2011-01-26
NO20016246L (en) 2002-03-04
WO2001001972A3 (en) 2001-12-06
US6855823B2 (en) 2005-02-15
US20050159445A1 (en) 2005-07-21
SK112002A3 (en) 2003-05-02
US7157582B2 (en) 2007-01-02
BR0012175A (en) 2002-03-05
HK1047036A1 (en) 2003-02-07
US6759418B2 (en) 2004-07-06
AR029373A1 (en) 2003-06-25
CN1230174C (en) 2005-12-07
KR20020024300A (en) 2002-03-29
EP1200073B1 (en) 2007-01-10
NZ515616A (en) 2004-05-28
CA2378613C (en) 2007-10-02
CZ20014488A3 (en) 2003-01-15
AU5873200A (en) 2001-01-22
US20030199546A1 (en) 2003-10-23
JP2003503449A (en) 2003-01-28
DE60032905D1 (en) 2007-02-22
MXPA01012726A (en) 2002-07-02
AU773304B2 (en) 2004-05-20
WO2001001972A2 (en) 2001-01-11
PT1200073E (en) 2007-03-30
DZ3209A1 (en) 2001-01-11
CN1359289A (en) 2002-07-17
DK1200073T3 (en) 2007-05-07
HUP0202253A2 (en) 2002-11-28
EA004290B1 (en) 2004-02-26
EA200200132A1 (en) 2002-06-27
CA2378613A1 (en) 2001-01-11

Similar Documents

Publication Publication Date Title
NO20016246L (en) Selective iGluR5 receptor antagonist for the treatment of migraine
NO20022925L (en) EP4 receptor selective agonists for the treatment of osteoporosis
NO20032360D0 (en) EP4 receptor selective agonists for the treatment of osteoporosis
NO20013380D0 (en) 2-aminobenzoxazinone derivatives for the treatment of obesity
PT1224174E (en) BENZODIAZEPIN DERIVATIVES AS ANTAGONISTS OF THE METHOTROPIC GLUTAMATE RECEPTOR
NO20034122L (en) Amalgamated pyridine derivatives for use as vanilloid receptor antagonists for the treatment of pain
CY2010003I1 (en) BETA-2 ADRENOREGIC RECEPTOR ANTAGONISTS
DE60026169D1 (en) SELECTIVE NEUROKININE ANTAGONISTS
PT1189916E (en) N-PYRAZOLE AGONISTS OF THE A2A RECEPTOR
NO20013381D0 (en) 2-oxybenzoxazinone derivatives for the treatment of obesity
DK1218382T3 (en) Bicyclic imidazo-3-ylamine derivatives
DE50015443D1 (en) BICYCLIC IMIDAZO-5-YL-AMINE DERIVATIVES
NO20020574D0 (en) Substituted 1,5-dihydropyrrole-2-derivatives which act as NMDA receptor antagonists for the treatment of the pain state
NO20015779L (en) Bradykinin receptor antagonists
NO20013997L (en) Receptor
IT1316831B1 (en) DEVICE FOR THE CONNECTION OF TWO CONSTRUCTION PARTS
NO20052012L (en) Indoles useful for treating androgen receptor related diseases
ATE284870T1 (en) ANTAGONISTS OF THE VITRONECTIN RECEPTOR
NO20005386L (en) Use of NMDA antagonists for the treatment of irritable bowel syndrome
NO20030717L (en) Compounds for the treatment of addiction disorders
IS5897A (en) Ureidopiperidine derivatives as selective NK3 receptor antagonists for humans
NO20022142D0 (en) Use of dopamine-D3 receptor agonists for the treatment of salt-dependent hypertension
NO990382D0 (en) Device for demineralization of water
DK1200402T3 (en) Substituted 1,5-dihydropyrrol-2-one derivatives acting as NMDA receptor antagonists for the treatment of pain conditions
NO20004422D0 (en) Process for the preparation of sulfanyl-type endothelin receptor antagonists

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application